Treatment of unresectable hepatocellular carcinoma with alpha-2B interferon and adriamycin. Final results of a pilot study

ANTIPYRINE METABOLISM IN LIVER CANCER rone. P.Coletta. R.Castellau, .x -1st Clinica Medlca & 1st. ‘Farmacologxa, Un Cattolica,Roma,lTALY We have employed the antlpyrlnetAP) test to Investigate the cancer influence upon the mixed hopatlc oxidatlve system (MEHOSI actiwty 1x3 the liver with pr,mary or secondary cancer The AP test was assessed In 176 patients, (median age 58 years, range 2% 78),45 had diffuse liver meta~tases seco”dary

QUANTITATION OF HEPATlC FlBROSlS IN CHRONIC HEPATITIS C (CHC): SUPPORT FOR THE CONTRIBUTION OF SERUM “YALURONIC ACID. J. Gu&5o,. P. OimI. C. Leeendn. I. G’b,dea,,. R. Pouvml. H+i,al Saint-Anloins - 7M12 Ptis ‘&NC&

to co*onic cancer and 33 had jxoven hepatocarclnoma (HCC) ,n clrrhotlc 11”er. Nc,ne

of them was jaundiced or asclt,c or termlna, neither was given antiblastic therapy 54 healthy volunteers and 44 patients wth clrrhosl~ without HCC acted a5 control gt-‘OUP’. After an Overnight fast the patient5 “et-e glwn a”tlPyrlne (18 mg,kg/os) Blood SamPIeS were drawn 3 h and 24 h after drug administration. The Brodx’s method ,.,a$ used

AP.

to estlmato the plasma concentration of found the folIowIng values of AP arrhosis 0.250 ml,h,k~ t 0.02; HCC-

We

clearance:

cIr?-hos,~ 0.259 ml/h/kg f 02; metastases 0.489 ml/h/kg rO2; healthy control 0 508 ml/h/kg 2.05 (P ( 0.001 1, AP half-life arrhozI$ 58.6+3.5 h, HCC-c1rrhoS*S 33 5 +I bh, metastaseS 16 5 +I 6 h: healthy control L&2+, Ih (p< 0 000 Cancer does not influence theM”EOS activity

512 7